Literature DB >> 15115969

Dynamics of hepatitis C virus infection.

Stefan Zeuzem1, Eva Herrmann.   

Abstract

Viremia shows only minor fluctuations in untreated patients chronically infected with hepatitis C virus. The steady state situation of balanced viral production and clearance in untreated patients can be disturbed by active antiviral treatment. After initiating interferon- alpha therapy, a typical biphasic decline of viremia can be observed and analyzed. Evaluation of mathematical models of viral dynamics during the initial phase of antiviral treatment shows high turnover rates of pre-treatment viral production and clearance of about 10(11) -10(13) virions each day and in-vivo half-lives of a few hours for free hepatitis C virions. During the first 24 to 48 hours of therapy, a dose-dependent first phase of interferon-alpha induced viral kinetics is characterized by a rapid exponential decline of serum viral load. Then viral decline enters a second phase of a relatively slow exponential decay during the following weeks of therapy which mainly reflects the death rate of infected hepatocytes. This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 15115969

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  4 in total

Review 1.  Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.

Authors:  Libin Rong; Alan S Perelson
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.

Authors:  Yi Zhou; Doug J Bartels; Brian L Hanzelka; Ute Müh; Yunyi Wei; Hui-May Chu; Ann M Tigges; Debra L Brennan; B Govinda Rao; Lora Swenson; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

3.  Noninvasive monitoring of hepatic damage from hepatitis C virus infection.

Authors:  J Alavez-Ramírez; J L Fuentes-Allen; J López-Estrada
Journal:  Comput Math Methods Med       Date:  2011-02-06       Impact factor: 2.238

4.  Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients.

Authors:  Denis Ouzan; Hacène Khiri; Guillaume Pénaranda; Hélène Joly; Philippe Halfon
Journal:  Comp Hepatol       Date:  2005-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.